Skip to main content
SpringerLink
Log in

Tiny and Forgotten: A Call for Focused Neonatal Policy Reform

  • Special Section: Pediatric Therapeutic Development: Commentary
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. US Food and Drug Administration Modernization Act of 1997. 105th Congress, PL 105-115, 21 USC 301 (1997); 2007 (Feb 21). https://www.gpo.gov/fdsys/pkg/PLAW-105publ115/pdf/PLAW-105publ115.pdf. Accessed July 25, 2018.

  2. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients—FDA. Final rule. Fed Regist. 1998;63(231):66631-66672. https://wayback.archive-it.org/7993/20170405140724/https://www.fda.gov/ohrms/dockets/ac/03/briefing/3927B1_05_1998%20Pediatric%20Rule.htm. Accessed July 25, 2018.

  3. Arshagouni P. Federal Court invalidates the FDA pediatric rule: AAPS v. FDA. 2002. https://www.law.uh.edu/healthlaw/perspectives/Children/021223Federal.html. Accessed July 25, 2018.

  4. Best Pharmaceuticals for Children Act, 21 USC 301 (2002); 21 USC 301 (Pub L No. 107-109). http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=107_cong_public_laws&docid=f:publ109.107. Accessed July 25, 2018.

  5. US Food and Drug Administration Safety and Innovation Act. PL 112–144. 2012 (112–144). http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed July 25, 2018.

  6. Pediatric Research Equity Act of 2003. Pub L No. 108–155 (2003). http://www.gpo.gov/fdsys/pkg/PLAW-108publ155/pdf/PLAW-108publ155.pdf. Accessed July 25, 2018.

  7. Biologics Price Competition and Innovation Act in The Patient Protection and Affordable Care Act, 111–148 (2010). https://www.gpo.gov/fdsys/pkg/PLAW-111publ148/html/PLAW-111publ148.htm. Accessed July 25, 2018.

  8. New pediatric labeling information database. 2018. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed July 25, 2018.

  9. Bucci-Rechtweg C. Enhancing the pediatric drug development framework to deliver better pediatric therapies tomorrow. Clin Ther. 2017;39:1920–1932.

    Article  Google Scholar 

  10. Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914–1915.

    Article  CAS  Google Scholar 

  11. Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168:130–136.

    Article  Google Scholar 

  12. Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Safe and Effective Medicines For Children. Washington, DC: National Academies Press Institute of Medicine; 2013.

  13. Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr. 2014;168:106–108.

    Article  Google Scholar 

  14. Ward RM, Benjamin D Jr, Barrett JS, et al. Considerations regarding safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates Ped Res. 2017;81:692–711.

    Article  Google Scholar 

  15. Ward RM, Sherwin CM. Ethics of drug studies in the newborn. Paediatr Drugs. 2015;17:37–42.

    Article  Google Scholar 

  16. Schmidt B, Roberts RS, Davis PG, et al. Prediction of late death or disability at age 5 years using a count of 3 neonatal morbidities in very low birth weight infants. J Pediatr 167:982–986e982.

  17. March of Dimes. The impact of premature birth on society. 2015. https://www.marchofdimes.org/mission/the-economic-and-societal-costs.aspx. Accessed July 25, 2018.

  18. Harrison W, Goodman D. Epidemiologic trends in neonatal intensive care, 2007–2012. JAMA Pediatr. 2015;169:855–862.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA

    Christina M. Bucci-Rechtweg

  2. University of Utah School of Medicine, Clinical Pharmacology, UT, Salt Lake City, USA

    Robert M. Ward MD

Authors
  1. Christina M. Bucci-Rechtweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. Ward MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina M. Bucci-Rechtweg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bucci-Rechtweg, C.M., Ward, R.M. Tiny and Forgotten: A Call for Focused Neonatal Policy Reform. Ther Innov Regul Sci 53, 615–617 (2019). https://doi.org/10.1177/2168479018821922

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479018821922

Keywords

Search

Navigation